Business Description
Cynata Therapeutics Ltd
NAICS : 325620
ISIN : AU000000CYP7
Description
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.91 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -4.6 | |||||
3-Year EPS without NRI Growth Rate | -40.9 | |||||
3-Year FCF Growth Rate | -45.2 | |||||
3-Year Book Growth Rate | -13.4 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 88.27 | |||||
9-Day RSI | 77.49 | |||||
14-Day RSI | 69.56 | |||||
6-1 Month Momentum % | 54.17 | |||||
12-1 Month Momentum % | 15.63 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 9.7 | |||||
Quick Ratio | 9.7 | |||||
Cash Ratio | 9.45 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -15.2 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -85.2 | |||||
ROA % | -77.28 | |||||
ROIC % | -678.41 | |||||
ROC (Joel Greenblatt) % | -4613.57 | |||||
ROCE % | -103.99 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 3.46 | |||||
Price-to-Tangible-Book | 3.92 | |||||
EV-to-EBIT | -1.86 | |||||
EV-to-EBITDA | -1.89 | |||||
EV-to-FCF | -2.24 | |||||
Price-to-Net-Current-Asset-Value | 3.92 | |||||
Price-to-Net-Cash | 3.92 | |||||
Earnings Yield (Greenblatt) % | -53.8 | |||||
FCF Yield % | -28.09 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Cynata Therapeutics Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil A$) | |||
EPS (TTM) (A$) | -0.087 | ||
Beta | 1.05 | ||
Volatility % | 59.28 | ||
14-Day RSI | 69.56 | ||
14-Day ATR (A$) | 0.01173 | ||
20-Day SMA (A$) | 0.203 | ||
12-1 Month Momentum % | 15.63 | ||
52-Week Range (A$) | 0.105 - 0.235 | ||
Shares Outstanding (Mil) | 179.63 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Cynata Therapeutics Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Cynata Therapeutics Ltd Stock Events
Event | Date | Price(A$) | ||
---|---|---|---|---|
No Event Data |
Cynata Therapeutics Ltd Frequently Asked Questions
What is Cynata Therapeutics Ltd(ASX:CYP)'s stock price today?
When is next earnings date of Cynata Therapeutics Ltd(ASX:CYP)?
Does Cynata Therapeutics Ltd(ASX:CYP) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |